Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Immunome (IMNM) Operating Margin (2023 - 2025)

Historic Operating Margin for Immunome (IMNM) over the last 3 years, with Q2 2025 value amounting to 1157.61%.

  • Immunome's Operating Margin rose 5348200.0% to 1157.61% in Q2 2025 from the same period last year, while for Sep 2025 it was 2419.9%, marking a year-over-year increase of 7145000.0%. This contributed to the annual value of 3382.37% for FY2024, which is 26010200.0% down from last year.
  • Immunome's Operating Margin amounted to 1157.61% in Q2 2025, which was up 5348200.0% from 1525.5% recorded in Q1 2025.
  • Over the past 5 years, Immunome's Operating Margin peaked at 129.96% during Q3 2023, and registered a low of 12857.05% during Q1 2024.
  • For the 3-year period, Immunome's Operating Margin averaged around 2492.75%, with its median value being 1608.96% (2025).
  • Its Operating Margin has fluctuated over the past 5 years, first tumbled by -126679200bps in 2024, then skyrocketed by 113315500bps in 2025.
  • Immunome's Operating Margin (Quarter) stood at 2473.94% in 2023, then decreased by -22bps to 3030.31% in 2024, then skyrocketed by 62bps to 1157.61% in 2025.
  • Its Operating Margin stands at 1157.61% for Q2 2025, versus 1525.5% for Q1 2025 and 3030.31% for Q4 2024.